| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 12/07/2005 | CN1230421C Amide compounds and medicinal use thereof |
| 12/07/2005 | CN1230199C Use of nitric oxide for treatment of airway constriction |
| 12/07/2005 | CN1230174C Selective iGLuR5 receptor antagonists for the treatment of migraine |
| 12/07/2005 | CN1230171C Treating diabetes by thiazolidine-diketo and dimethylbiguanide |
| 12/07/2005 | CN1230168C Agent with an antidepressive effect |
| 12/07/2005 | CN1230164C Combinations of(S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-1,4-dioxion[2,3-e]indol-8-one and neuroleptics |
| 12/07/2005 | CN1230162C Pharmaceutical composition for modified release of an insulin sensitizing agent and another antidiabetic agent |
| 12/07/2005 | CN1230152C Hydrogel particle formulations |
| 12/07/2005 | CN1230148C Composition containing N-vinyl iminazole polymer or copolymer and oxidation sensitive hydrophilic active ingredients for cosmetics and/or dermatology |
| 12/07/2005 | CA2509183A1 Topical anesthetic preparation for pretreatment for upper gastrointestinal endoscopy |
| 12/06/2005 | US6972335 useful as highly specific, non-toxic anticancer therapeutics and provides methods of inhibiting multidrug resistant cells |
| 12/06/2005 | US6972300 Compounds and compositions for delivering active agents |
| 12/06/2005 | US6972298 Method of treating or inhibiting neutrophil chemotaxis by administering a MEK inhibitor |
| 12/06/2005 | US6972179 RRP sequences and knockout mice and uses thereof |
| 12/06/2005 | US6972168 Materials and methods for nerve grafting, selection of nerve grafts, and in vitro nerve tissue culture |
| 12/06/2005 | CA2325282C Use of apo b secretion/mtp inhibitors |
| 12/06/2005 | CA2208274C Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes |
| 12/06/2005 | CA2079831C Biodegradable polymer composition |
| 12/01/2005 | WO2005113751A1 Cell culture environments for the serum-free expansion of mesenchymal stem cells |
| 12/01/2005 | WO2005113749A2 Stem cell populations and methods of use |
| 12/01/2005 | WO2005113601A2 Antibodies and molecules derived therefrom that bind to steap-1 proteins |
| 12/01/2005 | WO2005113506A1 Compounds and compositions as ppar modulators |
| 12/01/2005 | WO2005113030A1 Tissue closing preparation |
| 12/01/2005 | WO2005113023A1 Use of arginine and like substances and methylglyoxal and like substances in dialysis machines |
| 12/01/2005 | WO2005113014A1 siRNA TO VP-1 OF JC VIRUS AND MEDICINAL COMPOSITION CONTAINING THE SAME |
| 12/01/2005 | WO2005113009A1 Solid pharmaceutical formulation |
| 12/01/2005 | WO2005113006A2 Use of dipyridamole for treatment of resistance to platelet inhibitors |
| 12/01/2005 | WO2005113005A2 Transcutaneous and/or transdermal transport of materials |
| 12/01/2005 | WO2005113003A2 Method for augmenting b cell depletion |
| 12/01/2005 | WO2005113002A1 Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist |
| 12/01/2005 | WO2005112973A1 Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a gst-activated anticancer compound |
| 12/01/2005 | WO2005112949A1 Use of drug combinations for treating insulin resistance |
| 12/01/2005 | WO2005112918A1 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| 12/01/2005 | WO2005112917A1 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
| 12/01/2005 | WO2005112658A1 Method and composition for reducing e. coli disease and enhancing performance using bacillus |
| 12/01/2005 | WO2005112640A2 Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases |
| 12/01/2005 | WO2005112633A2 Compounds and compositions for delivering active agents |
| 12/01/2005 | WO2005103081A3 Human monoclonal antibodies against cd20 |
| 12/01/2005 | WO2005094797A3 Use of ampa-receptor antagonists for treating dementia |
| 12/01/2005 | WO2005086781A3 Regulatory t cells and their use in immunotherapy and suppression of autoimmune responses |
| 12/01/2005 | WO2005079767A3 Means for modulation of the effects of opioid-like substances |
| 12/01/2005 | WO2005048950A3 Tumor and infectious disease therapeutic compositions |
| 12/01/2005 | WO2005027831A3 Modulators of p-selectin glycoprotein ligand 1 |
| 12/01/2005 | WO2004096118B1 Composition for improving cognition and memory |
| 12/01/2005 | WO2004071384A3 New pharmaceutical compositions based on anticholinergics and tace-inhibitors |
| 12/01/2005 | WO2003075832A3 Methods and composition based on discovery of metabolism of nitroclycerin |
| 12/01/2005 | US20050267212 Omega-3 fatty acids in the treatment of depression |
| 12/01/2005 | US20050267211 Administration of products of the 5-lipoxygenase metabolic pathway to enhance antimicrobial defense |
| 12/01/2005 | US20050267201 Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| 12/01/2005 | US20050267196 Reducing tumor necrosis factor; phosphodiesterase inhibitor; anticancer agents; antidepressants; antiinflammatory agents; skin dsorders; antidepressants |
| 12/01/2005 | US20050267190 Solid-state form of celecoxib having enhanced bioavailability |
| 12/01/2005 | US20050267176 Dopamine-agonist combination therapy for improving sleep quality |
| 12/01/2005 | US20050267153 Administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents; inhibiting replication and secretion, reduced toxicity |
| 12/01/2005 | US20050267135 Combinations comprising antimuscarinic agents and PDE4 inhibitors |
| 12/01/2005 | US20050267134 Includes 4-{2,2-Dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-d][1,3]dioxol-4-ylmethoxy}-isophthalic acid as anticoagulant; thrombosis; renal dialysis |
| 12/01/2005 | US20050267127 Guanidino phenylalanin compounds used as urokinase inhibitors |
| 12/01/2005 | US20050267123 6-Membered heterocyclic compounds useful for selective inhibition of the coagulation cascade |
| 12/01/2005 | US20050267078 Combinations comprising antimuscarinic agents and beta-adrenergic agonists |
| 12/01/2005 | US20050267069 Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease |
| 12/01/2005 | US20050267066 Pharmaceutical composition comprising a CDK inhibitor and gemcitabine |
| 12/01/2005 | US20050267064 Containing unmethylated CpG dinucleotides, and an allergen; desensitization |
| 12/01/2005 | US20050267057 Redirect a Th2 response to a Th1 response; treating asthma, allergies, infections, cancer immunotherapy; contain unmethylated cytosine-guanine (CpG) dinucleotides |
| 12/01/2005 | US20050267052 Procyanidins as antineoplastic agents; topolisomerase, cylooxygenase, and/or lipoxygenase inhibitors; nitric oxide synthase modulators; hypotensive agents |
| 12/01/2005 | US20050267042 Method and preparation for binding acetaldehyde in saliva, stomach and large intestine |
| 12/01/2005 | US20050267038 Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use |
| 12/01/2005 | US20050267024 Polypeptide, cancer therapy, neovascularization defects, retinopathies, arthritis and psoraisis |
| 12/01/2005 | US20050267022 Identification of novel factors that block programmed cell death or apoptosis by targeting JNK |
| 12/01/2005 | US20050267016 Therapeutic oligopeptide for treatment of tumor disorders; contacting the tumor with a therapeutically effective amount of a CD10 cleavable prodrug, wherein tumor is comprised of one or more target cells which express CD10 for at least a portion of the target cell life cycle |
| 12/01/2005 | US20050267013 Methods for affecting various diseases utilizing LXR compounds |
| 12/01/2005 | US20050266486 Methods for treating obesity by inhibiting expression of obese gene product receptor variant |
| 12/01/2005 | US20050266485 polynucleotides encoding a hematopoietic cytokine receptor polypeptide, for use in the treatment of cancer; restoring normal blood cell levels in patients suffering from anemia, thrombocytopenia, and neutropenia or receiving chemotherapy for cancer; biodrugs; test detecting a genetic disorder, cancer |
| 12/01/2005 | US20050266399 HCV regulated protein expression |
| 12/01/2005 | US20050266099 Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head |
| 12/01/2005 | US20050266094 Topical composition and method for the treatment and prophylaxis of dermal irritations |
| 12/01/2005 | US20050266089 Contact lens and eye drop rewetter compositions and methods |
| 12/01/2005 | US20050266076 Resorbable delivery systems for the treatment of cancer |
| 12/01/2005 | US20050266069 Stable probiotic microsphere compositions and their methods of preparation |
| 12/01/2005 | US20050266067 Nanocell drug delivery system |
| 12/01/2005 | US20050266060 Transdermal delivery system for treatment of cognitive disorders |
| 12/01/2005 | US20050266024 Adjuvant |
| 12/01/2005 | US20050266018 Nutraceutical compositions with mangosteen |
| 12/01/2005 | US20050266002 Methods for the treatment of cancer using anti-CD40 antibodies |
| 12/01/2005 | US20050265987 Sulfatases and methods of use thereof |
| 12/01/2005 | US20050265982 cells cultured in serum, antibiotics, cell growth factors and epinephrine, exhibiting cell proliferation, migration and melanin production, used for treating skin disorders |
| 12/01/2005 | US20050265980 Cell culture environments for the serum-free expansion of mesenchymal stem cells |
| 12/01/2005 | US20050265979 Method for cryopreserving microencapsulated living animal cells enclosed in immunoisolation membranes, such microencapsulated living animal cells in immunoisolation membranes, and biohybrid artificial organ modules using such microencapsulated living animal cells in immunoisolation membranes |
| 12/01/2005 | US20050265978 Muscle-derived cells (MDCs) for treating muscle- or bone-related injury or dysfunction |
| 12/01/2005 | US20050265977 living cells collected from the choroid plexus of a mammal containing some choroid epithelial cells; implant secretes at least one product that has a beneficial effect on a neurological disease when transplanted into a recipient mammal suffering from such neurological disease |
| 12/01/2005 | US20050265965 Modified cytokines for use in cancer therapy |
| 12/01/2005 | US20050265961 Biodegradable poly(beta-amino esters) and uses thereof |
| 12/01/2005 | CA2567297A1 Tissue sealant |
| 12/01/2005 | CA2566873A1 Use of drug combinations for treating insulin resistance |
| 12/01/2005 | CA2566850A1 Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a gst-activated anticancer compound |
| 12/01/2005 | CA2566617A1 Method and composition for reducing e.coli disease and enhancing performance using bacillus |
| 12/01/2005 | CA2566333A1 Modulation of immunoglobulin production and atopic disorders |
| 12/01/2005 | CA2566081A1 Use of dipyridamole for treatment of resistance to platelet inhibitors |
| 12/01/2005 | CA2565446A1 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| 12/01/2005 | CA2565445A1 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
| 12/01/2005 | CA2565188A1 Compounds and compositions for delivering active agents |
| 12/01/2005 | CA2564365A1 Compounds and compositions as ppar modulators |